Standard research · Standard sources
Evidence for GLP-1 medications and long-term maintenance
Completed July 22, 2026
Evidence for GLP-1 Medications and Long-Term Maintenance
Synthesis Date: July 22, 2026
Executive Summary
GLP-1 receptor agonists (semaglutide, liraglutide, tirzepatide) are effective for long-term weight maintenance only with continuous use. Discontinuation leads to substantial weight regain (60–75% within 12–18 months) and loss of cardiometabolic benefits. Semaglutide 2.4 mg reduces major cardiovascular events by 20% in patients with established CVD and overweight/obesity without diabetes over ~4 years. Real-world discontinuation rates approach 65% at 1 year, creating a large efficacy-effectiveness gap. Optimal maintenance dosing, class-effect generalizability, and long-term safety beyond 4 years remain uncertain.
Key Findings
1. Weight Maintenance Requires Continuous Therapy
- STEP 4 (semaglutide, JAMA 2021): After 20-week run-in, continued semaglutide lost additional 7.9% vs. placebo regained 6.9% at week 68 (net difference 14.8 percentage points, p<0.001). Two-thirds of placebo arm regained ≥50% of run-in loss.
- SURMOUNT-4 (tirzepatide, JAMA 2024): 36-week lead-in produced 20.9% mean loss. Continued drug lost additional 5.5% vs. placebo regained 14.0% at week 88 (net difference 19.4 percentage points).
- STEP 1 extension (2022): One year off drug after 68 weeks of semaglutide: two-thirds of lost weight regained.
- Meta-analyses: 60–75% weight regained within 12–18 months of stopping across agents (Lancet eClinicalMedicine 2026, BMJ 2026, Obesity Reviews 2025).
2. Cardiovascular Benefit
- SELECT trial (NEJM 2023, n=17,604): Semaglutide 2.4 mg over mean 39.8 months reduced MACE by 20% (HR 0.80, p<0.001) in patients with CVD and BMI ≥27 without diabetes. Weight loss sustained at 10.2% throughout.
- Class effect uncertain: Tirzepatide CVOT (SURMOUNT-MMO) is ongoing; oral semaglutide at lower doses shows attenuated effect. Expert disagreement persists (JMCP 2026, Frontiers 2026).
3. Safety Profile
- GI side effects: Most common; 10–16% discontinuation due to adverse events in trials (SELECT: 16.6% semaglutide vs 8.2% placebo). Nausea, vomiting, diarrhea peak during titration.
- Pancreatitis: Large meta-analyses and multi-year data do not confirm early concern; FDA label retains warning. Cleveland Clinic (2025) suggests denying to patients with pancreatitis history "unwarranted."
- Thyroid C-cell tumors: FDA black box warning remains for MTC/MEN2. Human data from Mayo Clinic and multi-database cohorts suggest detection bias rather than causation; not definitive.
- Gallbladder disorders: Small but significant increase (2.8% vs 2.3% in SELECT).
- Aspiration risk: Documented during anesthesia; FDA label updated.
4. Population Differences
- Sex: Women lose ~11% vs men ~7% of starting weight (JAMA IM 2026, 64 RCTs).
- Age, race/ethnicity, baseline BMI/A1c: No significant differences in efficacy (same meta-analysis).
- Older adults ≥65: Higher AE-related discontinuation; efficacy preserved.
- Adolescents 6–17: Effective for BMI reduction; GI AEs more common; no signal for suicidality (JAMA Pediatrics 2025, 18 RCTs).
5. Real-World Effectiveness Gap
- Discontinuation rates: 46.5% at 1 year in T2D patients; 64.8% in obesity-only patients (JAMA Network Open 2024/2025, n=125,474). Only ~1 in 3 obesity patients persistent at 1 year; ~27% adherent (PDC≥80%).
- Efficacy vs effectiveness: Trial maintenance effects (15–19 percentage point difference vs placebo) likely overestimate real-world outcomes due to enriched populations, intensive lifestyle counseling, and monitoring not replicated in practice.
Expert Disagreements
| Issue | Pro – Lifetime Therapy | Con – Potential Taper/Stop |
|---|---|---|
| Continuation vs. cessation | Withdrawal trials show rapid regain; indefinite use required to maintain effect | SURMOUNT-4 lower-dose arm (5 mg tirzepatide) preserved ~17% loss vs 22% on full dose; some suggest tapered maintenance possible |
| CV class effect | Semaglutide proven; class effect plausible due to shared mechanism | No CVOT for tirzepatide in obesity; oral semaglutide lower dose less effective; class effect not proven |
| Pancreatitis risk | Large meta-analyses show no class-wide signal | FDA label still warns; case reports in real-world use |
| Optimal maintenance dosing | Max tolerated dose for maximal effect | Step-down to lower dose may preserve most loss; reduces cost/side effects (SURMOUNT-MAINTAIN) |
| Switching agents for maintenance | Oral orforglipron maintained weight loss after switching from injectables over 52 weeks (RCT 2025) | Durability beyond 1 year unknown; limited generalizability |
Trade-offs Decision Table
| Strategy | Pros | Cons |
|---|---|---|
| Continuous full-dose therapy | Maximal weight loss maintenance (15–24% total), proven CV benefit, sustained metabolic improvements | High cost ($900–$1,500/month US list), high GI side effect burden, unknown beyond ~4 years |
| Continuous lower-dose therapy | Reduced cost, fewer side effects, potentially better tolerability for maintenance | Less total weight loss maintained (e.g., ~17% vs 22% with tirzepatide 5 mg in SURMOUNT-4; evidence limited) |
| Drug holiday/discontinuation | No drug cost, no side effects, freedom from daily injections | ~60–75% weight regain within 12–18 months, loss of CV benefit, rebound of BP, lipids, glycemic control |
| Structured tapering with lifestyle | Could reduce regain rate; lower cost and side effect burden | No established protocol; SURMOUNT-MAINTAIN is first step; behavioral bridging not yet tested |
Practical Recommendations
- Indication: GLP-1 RAs should be presented as chronic therapy; patients should understand that discontinuation will likely lead to weight regain.
- Shared decision-making: Discuss tolerance of GI side effects, cost, and commitment before initiation.
- Dose selection: Start with standard titration; if full dose not tolerated, consider lower maintenance dose (e.g., tirzepatide 5 mg) based on SURMOUNT-MAINTAIN data—benefit may be partial but still superior to placebo.
- Lifestyle co-intervention: All trials included diet/exercise counseling; maximize lifestyle support to enhance real-world outcomes.
- Monitoring: Check for gallbladder symptoms; educate about aspiration risk before procedures requiring anesthesia.
- CV risk: For patients with established CVD and BMI ≥27 without diabetes, semaglutide 2.4 mg has proven benefit; consider as part of comprehensive risk reduction.
- Discontinuation: If patient chooses to stop, provide structured support including gradual dose tapering and intensive lifestyle counseling to potentially attenuate regain (no RCT evidence yet).
Unresolved Uncertainties
- Durability beyond 5 years: No RCT data beyond ~4 years (SELECT).
- Primary prevention CV benefit: SELECT enrolled only secondary prevention patients.
- Optimal dose-reduction or tapering protocols for maintenance.
- Intermittent or cycling dosing strategies (no evidence).
- Long-term thyroid cancer risk: Detection bias hypothesis not confirmed.
- Adherence interventions: No proven strategy to improve real-world persistence.
Caveats & Limitations
- All pivotal trials are industry-sponsored (Novo Nordisk, Eli Lilly), raising potential for publication bias.
- Withdrawal trial designs (STEP 4, SURMOUNT-4) use enriched populations (run-in tolerators/responders), limiting generalizability.
- Lifestyle co-intervention in trials not routinely replicated in real-world care.
- Meta-analyses pool largely same manufacturer-funded trials; no formal assessment of publication bias presented.
- FDA black box warning for MTC remains despite conflicting human evidence.